Mesenchymal stem cells augmentation for surgical procedures in patients with symptomatic chondral defects of the knee: a systematic review

Table 1 Generalities and patient baseline of the included studies

References	Journal	Design	Patients (n)	Follow-up (months)	Female (%)	Mean age	Type of augmentation
Akgun et al. [47]	Arch Orthop Trauma Surg	RCT	7	24	57	32	MSCs
			7	24	57	33	Control group
Buda et al. [2]	J Bone Joint Surg Am	Prospective	20	29	40		BM-MSCs
Buda et al. [54]	Europ J Orthop Surg Traumatol	Retrospective	28	48	43	38	BMAC
De windt et al. [20]	Stem Cells	Prospective	10	12	20	26	Allogenic MSCs
De windt et al. [50]	Stem Cells	Prospective	35	18	31	30	Allogenic MSCs
Enea et al. [43]	Knee	Retrospective	9	22	45	48	BMAC
Enea et al. [57]	Knee	Retrospective	9	29	44	43	BMAC
Gobbi et al. [18]	Cartilage	Prospective	15	24	33	48	BMAC
Gobbi et al. [19]	Am J Sports Med	Prospective	25	41	36	47	BMAC
Gobbi et al. [44]	Knee Surg Sports Traumatol Arthrosc	Prospective	20	48		50	BMAC
Haleem et al. [25]	Cartilage	Retrospective	5	12	20	25	BM-MSCs
Koh et al. [48]	Arthroscopy	RCT	40	27	65	38	A-MSCs
			40	27	60	39	Control group
Nejadnik et al. [45]	Am J Sports Med	Retrospective	36	24	50	43	Control group
			36	24	44	44	BM-MSCs
Skowronski et al. [58]	Ortop Traumatol Rehabil	Prospective	21	60	42	26	Control group
			25	60	44	26	Blood MSC
Teo et al. [46]	Clin Orthop Relat Res	Retrospective	20	24	20	17	Control group
			3	24	20		BM-MSC

BMAC—bone marrow aspirate concentrate; TT—tibial tubercle; A-MSCs—adipose derived MSCs; BM-MSCs—bone marrow derived MSCs; Coll—collagen; RCT—randomized controlled trial

ISSN: 1749-799X